Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine
This article is a part ofJoVE General. If you think this article would be useful for your research, please recommend JoVE to your institution's librarian.Recommend JoVE to Your Librarian
Current Access Through Your IP Address
Current Access Through Your Registered Email Address
Hasan, N., Humphrey, D., Riggs, K., Hu, C. Analysis of SNARE-mediated Membrane Fusion Using an Enzymatic Cell Fusion Assay. J. Vis. Exp. (68), e4378, doi:10.3791/4378 (2012).
The interactions of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins on vesicles (v-SNAREs) and on target membranes (t-SNAREs) catalyze intracellular vesicle fusion1-4. Reconstitution assays are essential for dissecting the mechanism and regulation of SNARE-mediated membrane fusion5. In a cell fusion assay6,7, SNARE proteins are expressed ectopically at the cell surface. These "flipped" SNARE proteins drive cell-cell fusion, demonstrating that SNAREs are sufficient to fuse cellular membranes. Because the cell fusion assay is based on microscopic analysis, it is less efficient when used to analyze multiple v- and t-SNARE interactions quantitatively.
Here we describe a new assay8 that quantifies SNARE-mediated cell fusion events by activated expression of β-galactosidase. Two components of the Tet-Off gene expression system9 are used as a readout system: the tetracycline-controlled transactivator (tTA) and a reporter plasmid that encodes the LacZ gene under control of the tetracycline-response element (TRE-LacZ). We transfect tTA into COS-7 cells that express flipped v-SNARE proteins at the cell surface (v-cells) and transfect TRE-LacZ into COS-7 cells that express flipped t-SNARE proteins at the cell surface (t-cells). SNARE-dependent fusion of the v- and t-cells results in the binding of tTA to TRE, the transcriptional activation of LacZ and expression of β-galactosidase. The activity of β-galactosidase is quantified using a colorimetric method by absorbance at 420 nm.
The vesicle-associated membrane proteins (VAMPs) are v-SNAREs that reside in various post-Golgi vesicular compartments10-15. By expressing VAMPs 1, 3, 4, 5, 7 and 8 at the same level, we compare their membrane fusion activities using the enzymatic cell fusion assay. Based on spectrometric measurement, this assay offers a quantitative approach for analyzing SNARE-mediated membrane fusion and for high-throughput studies.
1. Cell Culture and Transfection
2. Fluorescence Microscopic Analysis of Cell Surface SNARE Expression
3. FACS Analysis of Cell Surface SNARE Expression
4. Enzymatic Cell Fusion Assay
To develop a quantitative cell fusion assay, we take advantage of the strong transcriptional activation by the binding of tTA to TRE. In the absence of tTA, transcription of the LacZ gene in TRE-LacZ is silent. When tTA is present, it binds to the TRE and activates the transcription of LacZ. Figure 1 shows a flowchart of the enzymatic cell fusion assay. tTA is transfected into v-cells that express v-SNARE proteins at the cell surface, and TRE-LacZ is transfected into t-cells that express t-SNARE proteins at the cell surface. Fusion of the v- and t-cells results in the binding of tTA to TRE, the transcriptional activation of LacZ, and the expression of β-galactosidase.
Figure 2A illustrates the domain structure of flipped SNARE constructs. The preprolactin signal sequence is fused to the N-termini of SNAREs. These engineered SNAREs are called 'flipped' SNAREs because the orientation of their SNARE motifs against cellular membranes is flipped. When COS-7 cells are transfected with flipped SNARE plasmids, flipped SNARE proteins are expressed at the cell surface (Figure 2B). Flow cytometry is used to measure the expression levels of SNARE proteins at the cell surface (Figures 2C and D). In order to compare their membrane fusion capacities, VAMPs need to be expressed at the same level. Therefore, we titrated and optimized the concentration of each flipped SNARE plasmid used in transfection. Flipped SNARE plasmids are transfected at the following concentrations (per 10 cm2 growth area, i.e., per well in 6-well plates): VAMP1, 0.2 μg; VAMP3, 0.5 μg; VAMP4, 0.5 μg; VAMP5, 0.05 μg; VAMP7, 1.0 μg; VAMP8, 0.1 μg; syntaxin1, 0.5 μg; syntaxin4, 0.05 μg. tTA, TRE-LacZ and flipped SNAP-25 were cotransfected at 1 μg per 10 cm2 growth area. Under such conditions, VAMPs 1, 3, 4, 5, 7 and 8 are expressed at the same level, while syntaxins 1 and 4 are expressed at the same level at the cell surface (Figure 2D). As shown by confocal and phase contrast image analysis (Figure 2E), 80% of the COS-7 cells are transfected with flipped SNARE plasmids. Dual labeling imaging analysis (Figure 2F) indicates that 70% of the transfected v-cells express both tTA and flipped VAMP proteins. Because the LacZ gene in TRE-LacZ is not expressed before cell fusion, we are not able to determine the percentage of transfected t-cells that express both TRE-LacZ and flipped t-SNARE proteins.
The neuronal SNAREs (v-SNARE VAMP2, and t-SNAREs syntaxin1 and SNAP-25) that mediate synaptic exocytosis are used to test the feasibility of the assay. Indeed, when the v-cells expressing VAMP2 and t-cells expressing syntaxin1/SNAP-25 are combined, robust β-galactosidase expression is detected (Figure 3). However, when either VAMP2 or SNAP-25 is not expressed, only baseline β-galactosidase activity is detected, indicating that cell fusion and the expression of β-galactosidase rely on interactions of v- and t-SNAREs. These results indicate that the enzymatic cell fusion assay identifies fusogenic pairings between v- and t-SNAREs efficiently.
By expressing VAMP proteins at the same level at the cell surface (Figure 2D), we compare their membrane fusion activities. With the t-SNAREs syntaxin1/SNAP-25, VAMPs 1, 3, and 8 have comparable and the highest fusion activities, whereas VAMPs 4 and 7 have 50% and 30% lower fusion activities, respectively (Figure 4). In contrast, when VAMP5 is combined with the t-SNAREs, only baseline β-galactosidase activity is detected (Figure 4), suggesting that VAMP5 does not drive membrane fusion with the syntaxin1/SNAP-25.
Figure 1. Enzymatic cell fusion assay. tTA is cotransfected with flipped v-SNARE plasmids, and TRE-LacZ is cotransfected with flipped t-SNARE plasmids. The fusion of v- and t-cells leads to the binding of tTA to TRE and the expression of β-galactosidase, which is measured by a colorimetric method.
Figure 2. Expression of flipped SNAREs at the cell surface. (A) Domain structure of flipped SNAREs. The preprolactin signal sequence (SS) is fused to the N-termini of SNAREs, and a Myc tag is inserted between the signal sequence and the SNARE motifs (coiled-coil). (B) COS-7 cells are cotransfected with tTA and the empty vector pcDNA3.1(+) or flipped VAMP5 plasmid. 24 hr after transfection, unpermeabilized cells are stained with an anti-Myc monoclonal antibody. Representative single-slice confocal images are shown. (C and D) 24 hr after cotransfection with tTA and pcDNA3.1(+) or flipped VAMPs (v-cells), or 24 hr after cotransfection with TRE-LacZ, flipped SNAP-25 and syntaxins 1 or 4 (t-cells), unpermeabilized cells are stained with the anti-Myc antibody and analyzed by flow cytometry. (C) Representative FACS profiles of the cells transfected with pcDNA3.1(+) or flipped VAMP1 plasmid. The mean fluorescence intensity of each sample is determined using the CellQuest Pro software. (D) To express VAMPs at the same level and express syntaxins 1 and 4 at the same level at the cell surface, flipped SNARE plasmids are transfected at titrated concentrations. Shown are the mean fluorescence intensities of cell surface staining of the SNARE proteins. Error bars represent standard deviation of 4 independent experiments. (E and F) 24 hr after cotransfection with tTA and flipped VAMP5 plasmid, cells are permeablized with 0.2% Triton X-100 in PBS++ and (E) stained with the anti-Myc antibody, or (F) dual stained with the anti-Myc monoclonal antibody and a polyclonal antibody to the TET repressor (to detect tTA). (E) Shown are representative confocal and phase contrast images. The number of transfected cells that are labeled by the anti-Myc antibody (VAMP5) and the total number of cells in the phase contrast channel are counted (n = 60 cells), and transfection efficiency is calculated (80%). (F) The number of transfected cells that express both VAMP5 and tTA, and the total number of transfected cells that express VAMP5, tTA or both are counted (n = 75 transfected cells). The percentage of the transfected cells that express both VAMP5 and tTA is then calculated (70%). Scale bars, 20 μm. Click here to view larger figure.
Figure 3. Cell fusion depends on the interactions of v- and t-SNAREs. v-cells that express tTA and VAMP2 are incubated with t-cells that express TRE-LacZ, syntaxin1 and SNAP-25. After 24 h, the cells are lysed and the activity of β-galactosidase in the cell lysates is determined using a colorimetric method by absorbance at 420 nm. Only baseline b-galactosidase activity is detected when either flipped VAMP2 or SNAP-25 plasmid is omitted from transfection.
Figure 4. Comparison of fusion activities of VAMPs. Under optimized transfection conditions, VAMPs 1, 3, 4, 5, 7 and 8 are expressed at the same level at the cell surface of v-cells. 24 hr after combining the v-cells with the t-cells that express syntaxin1/SNAP-25, cell fusion is quantified using the enzymatic cell fusion assay. Error bars represent standard deviation of 4 independent experiments. **P<0.01; *** P<0.001 vs. VAMP1.
The original cell fusion assay6 determines SNARE-mediated cell fusion events by fluorescence microscopy. Here we describe an innovative assay that quantifies SNARE-mediated cell fusion events by activated expression of β-galactosidase and spectrometric measurement. Using this assay, we routinely analyze 15 - 20 v- and t-SNARE combinations in a single experiment. Using flow cytometry to measure SNARE expression at the cell surface, we titrate the expression levels of VAMPs and compare their membrane fusion capacities (Figures 2 and 4). Furthermore, using the enzymatic cell fusion assay, we determined the dependence of cell fusion activity on cell surface density of VAMP1 protein, and observed no cooperativity of VAMP1 protein in the cell fusion reaction8, suggesting that concerted action of multiple SNARE complexes is not required to fuse cellular membranes.
There are putative N-glycosylation motifs (Asn-X-Ser/Thr) in SNARE proteins. Because N-glycosylation inhibits the fusion activities of flipped SNARE proteins6, two approaches have been used to prevent the glycosylation of flipped SNARE proteins. First, glycosylation-site mutations are introduced into flipped SNARE constructs6. Second, as described in the current protocol, the N-glycosylation inhibitor tunicamycin (6.7 μg/ml) is included in the cell fusion reaction. In addition, 0.67 mM DTT is added in the cell fusion reaction to prevent the formation of disulfide bonds among flipped SNARE proteins, which would inhibit SNARE fusion activities. Our experiments show that the addition of 6.7 μg/ml tunicamycin and 0.67 mM DTT in cell culture medium does not interfere with the proliferation and survival of COS-7 cells. We routinely terminate the cell fusion reaction at 24 hr after combining v- and t-cells. However, significant SNARE-mediated cell fusion is detected 6 hr after combining v- and t-cells8. Because the enzymatic cell fusion reaction depends on the expression of β-galactosidase after cell fusion, the time course of this readout system lags the time course of membrane fusion mediated by flipped SNARE proteins.
The enzymatic cell fusion assay offers a quantitative reconstitution assay for examining the membrane fusion activities of potential v- and t-SNARE interactions in mammalian cells. By coexpressing regulatory proteins (e.g., Munc18) and SNAREs at the cell surface or by including recombinant regulatory proteins in the cell fusion reaction, this assay can be used to elucidate the regulatory mechanisms of SNARE-mediated membrane fusion. In addition, this assay should have applications in high-throughput screening for inhibitors or activators of SNARE-mediated membrane fusion.
No conflicts of interest declared.
This work is supported by startup funds from the University of Louisville and CA135123 from the National Institutes of Health (to C.H.).
|Enzyme-free cell dissociation solution||Invitrogen||13151-014|
|Rabbit anti-TET Repressor polyclonal antibody||Millipore||AB3541|
|FITC-conjugated donkey anti-mouse IgG (H+L)||Jackson ImmunoResearch||715-095-150|
|Laser scanning confocal microscope||Olympus||FV1000|
|FACSCalibur flow cytometer||BD Biosciences|
|β-Galactosidase Enzyme Assay System with Reporter Lysis Buffer||Promega||E2000|
|Model 100-40 UV-VIS spectrophotometer||Hitachi||C740843|